Compare stocks

Swedish Orphan Biovitrum AB is a biotechnology company primarily focused on developing and commercializing specialty pharmaceuticals for rare diseases. The company is active in therapeutics for hematology, immunology, and genetic and metabolic disorders. Swedish Orphan Biovitrum was founded in 2001 and is headquartered in Stockholm, Sweden. The company operates globally, reaching markets in Europe, North America, and other regions. A key aspect of its strategic positioning is its commitment to addressing unmet medical needs in rare diseases, which often provides a unique market niche. The company invests significantly in research and development to fuel growth and innovation in its therapeutic areas.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.